POSACONAZOLE AND INVASIVE FUNGAL INFECTION

Meneses. Clara, Briegas. Daniel, Martín. Susana, M. Belén, B. Cristina, R. Lydia

Purpose

To analyze posaconazole use, assessing the compliance with our Hospital Pharmacy and Therapeutics Committee (PTC) established criteria, and also its efficacy, safety and budget impact.

Material and methods

Retrospective study of patients under posaconazole treatment in our hospital between Sep 2013- Sep 2014.

Data collecting: age, gender, diagnosis, indication, posology, treatment length, previous treatment lines, clinical analytics and microbiology, outcomes, adverse events, drug interactions and laboratory selling price.

Results

- POPULATION
  - Male: 81%
  - Female: 19%
  - Average age: 58 years
  - Expense per patient: 3000 €

- Iatrogenic agranulocytosis: 9%
- Aplastic anemia: 9%
- Current IFI: 18%
- Myelodysplastic syndrome: 27%
- LMA: 37%

Conclusion

PTC criteria was met in most of the cases, but posaconazole use for non approved indications represented an additional cost of 18155€, which remarks the need of a tight control of criteria compliance.